Metabolic and Weight Observations in Four Women Using Triphasic Norgestimate/Ethinylestradiol: A Six-month Descriptive Case Series.

IF 2.8 Q3 OBSTETRICS & GYNECOLOGY
Open access journal of contraception Pub Date : 2026-08-07 eCollection Date: 2026-01-01 DOI:10.2147/OAJC.S604855
Maria Cristina Cesana, Debora Vicini, Simona Ruisi, Martina Fantauzzi, Antonio Pellegrino
{"title":"Metabolic and Weight Observations in Four Women Using Triphasic Norgestimate/Ethinylestradiol: A Six-month Descriptive Case Series.","authors":"Maria Cristina Cesana, Debora Vicini, Simona Ruisi, Martina Fantauzzi, Antonio Pellegrino","doi":"10.2147/OAJC.S604855","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Triphasic combined oral contraceptives (COCs) containing norgestimate and ethinylestradiol are established therapeutic options. Previous studies and reviews have described their metabolic profile, but contemporary routine-practice descriptions remain limited. This report was not designed to test efficacy or to generate population-level evidence.</p><p><strong>Objective: </strong>To describe short-term changes in selected metabolic and clinical parameters over six months in four women using a triphasic norgestimate/35 µg ethinylestradiol COC.</p><p><strong>Patients and methods: </strong>This retrospective descriptive case series included four women of reproductive age, without known metabolic disorders, who initiated triphasic norgestimate/35 µg ethinylestradiol in routine clinical practice and had complete records at baseline, 3 months, and 6 months. Fasting glucose, triglycerides, total cholesterol, LDL/HDL ratio, blood pressure, and body weight were extracted from clinical records. Results are summarized descriptively as medians with ranges and patient-level changes. No inferential analyses were planned or performed.</p><p><strong>Results: </strong>Fasting glycaemia remained within the physiological range in all four patients at each time point. Median triglycerides increased from 98 mg/dL at baseline to 123 mg/dL at 3 months and decreased to 88 mg/dL at 6 months; one patient had a value of 151 mg/dL at 3 months. Median total cholesterol increased from 173 mg/dL at baseline to 195.5 mg/dL at 6 months, with two patients above 200 mg/dL at 6 months. LDL/HDL ratios remained below 2 at 6 months, although individual changes were heterogeneous. Body weight showed small individual fluctuations from baseline to 6 months (-2 to +1 kg).</p><p><strong>Conclusion: </strong>This four-patient retrospective case series provides descriptive short-term observations only. The findings should not be interpreted as evidence of metabolic efficacy, safety, or generalizability. They are hypothesis-generating and require evaluation in larger prospective studies with standardized follow-up and assessment of potential confounders.</p>","PeriodicalId":74348,"journal":{"name":"Open access journal of contraception","volume":"17 ","pages":"604855"},"PeriodicalIF":2.8000,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open access journal of contraception","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OAJC.S604855","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Triphasic combined oral contraceptives (COCs) containing norgestimate and ethinylestradiol are established therapeutic options. Previous studies and reviews have described their metabolic profile, but contemporary routine-practice descriptions remain limited. This report was not designed to test efficacy or to generate population-level evidence.

Objective: To describe short-term changes in selected metabolic and clinical parameters over six months in four women using a triphasic norgestimate/35 µg ethinylestradiol COC.

Patients and methods: This retrospective descriptive case series included four women of reproductive age, without known metabolic disorders, who initiated triphasic norgestimate/35 µg ethinylestradiol in routine clinical practice and had complete records at baseline, 3 months, and 6 months. Fasting glucose, triglycerides, total cholesterol, LDL/HDL ratio, blood pressure, and body weight were extracted from clinical records. Results are summarized descriptively as medians with ranges and patient-level changes. No inferential analyses were planned or performed.

Results: Fasting glycaemia remained within the physiological range in all four patients at each time point. Median triglycerides increased from 98 mg/dL at baseline to 123 mg/dL at 3 months and decreased to 88 mg/dL at 6 months; one patient had a value of 151 mg/dL at 3 months. Median total cholesterol increased from 173 mg/dL at baseline to 195.5 mg/dL at 6 months, with two patients above 200 mg/dL at 6 months. LDL/HDL ratios remained below 2 at 6 months, although individual changes were heterogeneous. Body weight showed small individual fluctuations from baseline to 6 months (-2 to +1 kg).

Conclusion: This four-patient retrospective case series provides descriptive short-term observations only. The findings should not be interpreted as evidence of metabolic efficacy, safety, or generalizability. They are hypothesis-generating and require evaluation in larger prospective studies with standardized follow-up and assessment of potential confounders.

四名妇女使用三相诺格估计/炔雌醇的代谢和体重观察:六个月的描述性病例系列。
背景:含炔雌醇和炔雌醇的三期联合口服避孕药(COCs)是公认的治疗选择。先前的研究和综述已经描述了它们的代谢特征,但当代的常规实践描述仍然有限。本报告的目的不是检验疗效或产生人群水平的证据。目的:描述4名妇女在6个月内使用三相诺格/35µg炔雌醇COC的选定代谢和临床参数的短期变化。患者和方法:该回顾性描述性病例系列包括4名育龄妇女,没有已知的代谢紊乱,在常规临床实践中开始了三期norgestimate/35µg炔雌醇,并在基线、3个月和6个月有完整的记录。从临床记录中提取空腹血糖、甘油三酯、总胆固醇、LDL/HDL比值、血压和体重。结果被描述性地总结为具有范围和患者水平变化的中位数。没有计划或执行推论分析。结果:4例患者在各时间点的空腹血糖均保持在生理范围内。中位数甘油三酯从基线时的98 mg/dL增加到3个月时的123 mg/dL, 6个月时降至88 mg/dL;1例患者3个月时血压值为151 mg/dL。中位总胆固醇从基线时的173 mg/dL增加到6个月时的195.5 mg/dL,有2例患者6个月时高于200 mg/dL。LDL/HDL比率在6个月时保持在2以下,尽管个体变化是异质的。从基线到6个月(-2至+1公斤),个体体重波动较小。结论:这4例患者回顾性病例系列仅提供描述性短期观察结果。研究结果不应被解释为代谢有效性、安全性或普遍性的证据。它们产生假设,需要在更大的前瞻性研究中进行评估,并进行标准化随访和评估潜在的混杂因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书